Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

balixafortide (POL 6326)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Fosun Pharma, Spexis

Drug class:

CXCR4 antagonist

Related drugs:

HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	POL 6326 Sensitive: B - Late Trials POL 6326 Sensitive : B	POL 6326 Sensitive: B - Late Trials POL 6326 Sensitive : B
CXCR4 positive	HER2 Negative Breast Cancer	CXCR4 positive	HER2 Negative Breast Cancer	POL 6326 Sensitive: C3 – Early Trials POL 6326 Sensitive : C3	POL 6326 Sensitive: C3 – Early Trials POL 6326 Sensitive : C3
CXCR4 expression	HER2 Negative Breast Cancer	CXCR4 expression	HER2 Negative Breast Cancer	POL 6326 Sensitive: C3 – Early Trials POL 6326 Sensitive : C3	POL 6326 Sensitive: C3 – Early Trials POL 6326 Sensitive : C3